文献速递骨软组织肉瘤与黑色素瘤

恩考芬尼联合比美替尼在BRAF突变黑色素瘤脑转移患者中的疗效:荷兰黑色素瘤治疗登记研究结果

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.
PubMed 文献 · Eur J Cancer · 2025-05-19

本研究基于荷兰黑色素瘤治疗登记研究,纳入2019至2022年间接受恩考芬尼联合比美替尼治疗的BRAF V600突变黑色素瘤脑转移患者190例,排除既往使用其他BRAF/MEK抑制剂者。总体客观缓解率为69.4%,中位无进展生存期5.5个月,中位总生存期11.9个月。结论认为该方案在真实世界脑转移患者中具有临床活性,预后由症状性脑转移、年龄、ECOG PS和LDH水平决定。

要点

  • 恩考芬尼联合比美替尼在BRAF突变黑色素瘤脑转移患者中客观缓解率为69.4%。
  • 中位无进展生存期5.5个月,中位总生存期11.9个月。
  • 症状性脑转移、年龄≥70岁、ECOG PS≥2及LDH升高与更差生存显著相关。

核心结论

  • 恩考芬尼联合比美替尼在真实世界黑色素瘤脑转移患者中具有临床活性。
  • 患者预后由症状性脑转移、年龄、ECOG PS和LDH水平决定。

研究设计与样本

  • 研究为基于荷兰全国性荷兰黑色素瘤治疗登记研究的队列分析。
  • 纳入2019年至2022年间接受恩考芬尼联合比美替尼治疗的BRAF V600突变黑色素瘤脑转移患者。
  • 排除既往接受过其他BRAF/MEK抑制剂治疗的患者,共纳入190例患者。
  • 分析指标包括客观缓解率、无进展生存期和总生存期,采用多变量Cox回归识别与生存相关的因素。
  • 亚组分析包括无症状与症状性脑转移以及一线与后线治疗。

主要发现

  • 症状性脑转移存在于63%的患者中。
  • 恩考芬尼联合比美替尼作为一线治疗用于64%的患者,36%的患者既往接受过免疫治疗。
  • 总体客观缓解率为69.4%,中位无进展生存期为5.5个月(95%CI 4.9-6.2),中位总生存期为11.9个月(95%CI 10.0-15.7)。
  • 年龄≥70岁、ECOG PS≥2、症状性脑转移和LDH升高与更差生存显著相关。
  • 既往接受免疫治疗患者的中位无进展生存期为6.9个月(95%CI 4.3-9.6),中位总生存期为17.9个月(95%CI 13.7-31.2);初治患者分别为4.9个月(95%CI 4.3-5.5)和10.1个月(95%CI 8.1-13.0)。

关键数值与推荐

  • 总体客观缓解率为69.4%。
  • 中位无进展生存期为5.5个月(95%CI 4.9-6.2),中位总生存期为11.9个月(95%CI 10.0-15.7)。
  • 年龄≥70岁、ECOG PS≥2、症状性脑转移和LDH升高与更差生存显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Data on the effectiveness of encorafenib/binimetinib in melanoma patients with brain metastases (BMs) are limited. METHODS: All patients with BRAF V600-mutated melanoma and BMs treated with encorafenib/binimetinib between 2019 and 2022 in the Netherlands were included from the nationwide Dutch Melanoma Treatment Registry. Patients previously treated with other BRAF/MEK inhibitors were excluded. We analyzed objective response rates (ORR), progression-free survival (PFS), and overall survival (OS). Multivariable Cox regression identified factors associated with survival. Subgroup analyses included asymptomatic versus symptomatic BMs and line of treatment (first-line versus later-line). RESULTS: In total, 190 patients were included. Symptomatic BMs were present in 63 % of patients. Encorafenib/binimetinib was the first-line treatment in 64 % of all patients, while 36 % had prior immunotherapy. Overall, the ORR was 69.4 %, median PFS was 5.5 months (95 %CI 4.9-6.2), and median OS 11.9 months (95 %CI 10.0-15.7). Age ≥ 70, ECOG PS ≥ 2, symptomatic BMs, and elevated LDH were significantly associated with worse survival. Patients with prior immunotherapy had a median PFS of 6.9 months (95 %CI 4.3-9.6) and OS of 17.9 months (95 %CI 13.7-31.2), while this was 4.9 months (95 %CI 4.3-5.5) and 10.1 months (95 %CI 8.1-13.0) in treatment-naïve patients. Median PFS and OS in patients with asymptomatic versus symptomatic BMs were 6.1 months (95 %CI 4.9-9.8) and 20.5 (95 %CI 14.0-NA) versus 5.3 months (95 %CI 4.9-6.3) and 10.7 (95 %CI 8.9-13.7), respectively. CONCLUSIONS: Encorafenib/binimetinib has clinical activity in real-world melanoma patients with BMs. Their prognosis is determined by the presence of symptomatic BMs, age, ECOG PS, and LDH levels.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bloem M, Suijkerbuijk KPM, Aarts MJB, et al. Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry. Eur J Cancer. 2025. PMID: 40411977. doi:10.1016/j.ejca.2025.115514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。